VICTORIA, Feb. 20, 2020 /PRNewswire/ – ImmunoPrecise Antibodies Ltd (the “Company”), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, announces its commitment to the development of innovative vaccines...
This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor. Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold” colorectal tumors “hot.” TEL AVIV, Israel, Feb. 20, 2020 (GLOBE...
VANCOUVER, Washington, Feb. 21, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple...
Santa Ana, CA — (SBWIRE) — 02/20/2020 — Arthritis is one of the most leading causes of pain and disability worldwide. There are more than 100 different types of arthritis and related diseases. However, the most common types of arthritis are...
– Balstilimab and zalifrelimab combination yield >20% response rates – Balstilimab and zalifrelimab combination has best-in-class potential for the treatment of second-line cervical cancer – On track to submit 2 BLAs for these agents in 2020...
Email
Text